90 GHP / Healthcare and Pharmaceutical Awards 2021 , Dr Ashleys Limited is amulti-product, multi-market, multi-location, andmulti-segment pharmaceutical company based inHong Kong. Recognised as the Best Pharmaceutical Medical & Surgical Products Provider, Dr Ashleys is one the fastest growing andmost attractively profitable companies for one key reason - knowledge. Best Pharmaceutical Medical & Surgical Products Provider - Central Hong Kong Incorporated in April 2012, Dr Ashleys Limited is known for supplying pharmaceutical products, sourcing and marketing various Agro commodities, and extensive trading experience in ferrous and non-ferrous scrap. Additionally, the company deals with Africa, India, Korea, China, Dubai, UK, Germany, Singapore, Malaysia, Mauritius, Spain, and Egypt. Dr Ashleys is an integrated pharmaceutical company with manufacturing and marketing capabilities in CRAMS and active pharmaceutical ingredients (APIs). It is currently graduating from its lozenge-making competence to a Novel Drug Delivery System (NDDS) that creates formulations for common illnesses. The company manufactures second-generation anti-malarial APIs like quinine and salts and third-generation anti-malarial products like Artemisinin-based salts. In addition, Dr Ashleys also manufactures niche APIs as well as ace inhibitors, CNS, antiretrovirals. Additionally, Dr Ashleys engages in contractual manufacture under loan licence and distributes branded generic products across India through a proprietary network comprising 350 distributors and over 1,200 stockists. Furthermore, the company also exports branded formulations to 60 countries. Dr Ashleys has chosen to build knowledge in areas marked by significant, (relatively) unmet needs of society like malaria, cough and cold, chain-smoking, among others and have selected to commercialise products around a distinctive proposition for consumers. Overall, the company has progressively increased its investments in knowledge- building infrastructure. As a result, its R&D centres in Hyderabad are equipped with state-of-the-art equipment and processes looking into developing innovative products, NDDS, new dosage forms, new packaging, analytical methods, and conducting stability studies and procedural validation. Additionally, its new 10,000sq ft DSIR-compliant R&D centre in Hyderabad and 20,000sq ft at Hyderabad will be lab-scale equipment to formulate and develop tablets, liquids, topical formulations, lozenges, and gels backed by a 200-title library – a sizeable knowledge repository. Dr Ashleys’ labs strive to be the premier provider of new medical therapies in the anti-cancer and anti-malarial segments worldwide to the pharmaceutical industry. It wants to combine the strength of its expertise, experience, and innovation to advance in the worldwide success of the pharmaceutical industries in preventing and curing disease. Dr Ashleys has reinforced its knowledge pool through selective recruitment. Its R&D team comprises 70 members with 15 PhDs and 25 master’s degree holders, possessing more than 1,000 years of cumulative experience in pharmaceutical research. The company has broadened its knowledge base to ensure integrated solutions delivery as its R&D activities are segregated into Active Pharmaceutical Ingredient Department, Analytical Method Development Department and Formulation Development Department. The R&D team converges skills in allopathic and ayurvedic competencies to develop products, and the team comprises members with expertise in taste and product stability. Dr Ashleys values doing what’s proper and demanding honesty, maintaining confidentiality, and adherence to professional standards of excellence. It strives to understand its clients’ requirements and to meet or exceed their expectations with high-quality deliverables and service. It is flexible and always looks for proactive, responsible solutions to ensure client satisfaction every time. Company: Dr Ashleys Limited Contact: Kannan Vishwanatth Web Address: drashleys.com Email:
[email protected] Aug21843